Prodrugs and derivatives of hydroxymethylfurfural (5-HMF) to develop a novel, bioavailable treatment for sickle cell disease
Ended Project Grant Awarded Last action
- Award ID
- R43HL150961
- Recipient
-
Illexcor Therapeutics, Inc. UEI GFKZPH9N1VX3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,962
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Place of performance
- Richmond, VA 23219, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $299,962 |
Quick answers
Who received award R43HL150961?
R43HL150961 was awarded to Illexcor Therapeutics, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on March 1, 2020.
How much is award R43HL150961 worth?
$299,962 has been obligated on R43HL150961.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award